Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.45), $0.14 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $87.87 million versus the consensus estimate of $86.89 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.